- Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
- Bondholders approve amended terms of the 2024 convertible bonds
- Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
- Idorsia publishes an invitation to a bondholder meeting
- Idorsia publishes a Financial Status required for an upcoming bondholder meeting
- Idorsia takes steps to address short-term liquidity needs
- Idorsia thanks Guy Braunstein for his years of service as he retires
- US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration
More ▼
Key statistics
On Friday, Idorsia Ltd (IDIA:SWX) closed at 2.22, 71.56% above the 52 week low of 1.29 set on Jan 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.33 |
---|---|
High | 2.38 |
Low | 2.12 |
Bid | 2.39 |
Offer | 2.39 |
Previous close | 2.35 |
Average volume | 521.32k |
---|---|
Shares outstanding | 188.97m |
Free float | 120.68m |
P/E (TTM) | -- |
Market cap | 444.45m CHF |
EPS (TTM) | -2.11 CHF |
Data delayed at least 15 minutes, as of May 17 2024 16:32 BST.
More ▼